Table 2

Antitumor activity and toxicity of different schedules of topotecan administered intravenously in mice

Schedule of administrationaLife span (days)Increased life span (%)Maximum body weight loss (%)
Controls59 ± 2.1
12.5 mg/kg × 160.1 ± 14.601
2.5 mg/kg (d × 5)b82.3 ± 3.4407.3
1.25 mg/kg (d × 5)2b77.8 ± 8322.4
0.625 mg/kg (d × 5)4b96 ± 6630
  • a Topotecan treatment began 3 days after tumor implantation.

  • b Topotecan was administered i.v. 5 days/week, for 1, 2, or 4 consecutive weeks.